Ipsen Pharma: Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...
Breakthrough T1D Announces National Volunteer Award Recipients At Annual One Conference
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to seven outstanding volunteer leaders whose impact has pushed ...